Laboratorios Farmaceuticos ROVI SA banner

Laboratorios Farmaceuticos ROVI SA
OTC:LABFF

Watchlist Manager
Laboratorios Farmaceuticos ROVI SA Logo
Laboratorios Farmaceuticos ROVI SA
OTC:LABFF
Watchlist
Price: 90.61 USD
Market Cap: $4.6B

P/FCFE

34.1
Current
3%
Cheaper
vs 3-y average of 35.1

Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.

P/FCFE
34.1
=
Market Cap
$4.1B
/
Free Cash Flow to Equity
€118.3m

Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.

P/FCFE
34.1
=
Market Cap
$4.1B
/
Free Cash Flow to Equity
€118.3m

Valuation Scenarios

Laboratorios Farmaceuticos ROVI SA is trading below its 3-year average

If P/FCFE returns to its 3-Year Average (35.1), the stock would be worth $93.2 (3% upside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-54%
Maximum Upside
+8%
Average Downside
13%
Scenario P/FCFE Value Implied Price Upside/Downside
Current Multiple 34.1 $90.61
0%
3-Year Average 35.1 $93.2
+3%
5-Year Average 30.7 $81.69
-10%
Industry Average 36.8 $97.72
+8%
Country Average 15.6 $41.5
-54%

Forward P/FCFE
Today’s price vs future free cash flow to equity

Not enough data available to calculate forward P/FCFE

Peer Comparison

All Multiples
P/FCFE
P/E
All Countries
Close
Market Cap P/FCFE P/E
ES
Laboratorios Farmaceuticos ROVI SA
OTC:LABFF
4B USD 34.1 28.7
US
Eli Lilly and Co
NYSE:LLY
804.2B USD 65.4 42.8
US
Johnson & Johnson
NYSE:JNJ
547.4B USD 21.2 26.3
CH
Roche Holding AG
SIX:ROG
248.4B CHF 27.5 20.1
UK
AstraZeneca PLC
LSE:AZN
216.3B GBP 51.5 28
US
Merck & Co Inc
NYSE:MRK
274.6B USD 11.9 14.8
CH
Novartis AG
SIX:NOVN
216.3B CHF 9.4 20.7
IE
Endo International PLC
LSE:0Y5F
244.4B USD -766.6 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 23.6 11.8
US
Pfizer Inc
NYSE:PFE
149.3B USD 24.6 19.5
US
Bristol-Myers Squibb Co
NYSE:BMY
115.9B USD 20 17.3
P/E Multiple
Earnings Growth PEG
ES
Laboratorios Farmaceuticos ROVI SA
OTC:LABFF
Average P/E: 23
28.7
22%
1.3
US
Eli Lilly and Co
NYSE:LLY
42.8
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
26.3
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
28
25%
1.1
US
Merck & Co Inc
NYSE:MRK
14.8
14%
1.1
CH
Novartis AG
SIX:NOVN
20.7
14%
1.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.8
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.5
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
17.3
16%
1.1

Market Distribution

Higher than 84% of companies in Spain
Percentile
84rd
Based on 497 companies
84rd percentile
39.2
Low
1.4 — 10.4
Typical Range
10.4 — 26.3
High
26.3 —
Distribution Statistics
Spain
Min 1.4
30th Percentile 10.4
Median 15.6
70th Percentile 26.3
Max 531.1

Laboratorios Farmaceuticos ROVI SA
Glance View

Laboratorios Farmacéuticos ROVI SA has carved a niche for itself in the pharmaceutical industry through its focus on researching, developing, manufacturing, and marketing a broad range of small molecule drugs and specialized products. Founded in Spain, ROVI has channeled its efforts towards creating innovative solutions in the healthcare sector, with heparin-based products emerging as a cornerstone of its portfolio. The company's operational model is built on vertical integration, allowing it to control the entire lifecycle of its offerings, from production to commercialization. This approach not only ensures quality and compliance with stringent regulatory standards but also enables ROVI to adapt nimbly to market demands and leverage its proprietary science to secure a competitive edge. The revenue streams of ROVI are diversified across its proprietary products, contract manufacturing services, and its portfolio of licensed products. A significant portion of revenue stems from its commitment to injectable drug products like Bemiparin, a low molecular weight heparin, which has found a foothold in various international markets. Moreover, ROVI capitalizes on partnerships and alliances with major pharmaceutical giants, augmenting its contract manufacturing capabilities and tapping into more extensive distribution networks. Not resting on its laurels, ROVI invests heavily in research and development to fortify its pipeline with innovative formulations, thus ensuring sustained growth and a resilient positioning in the global pharmaceutical landscape. This blend of strategic partnerships, internal innovation, and market-responsive production underscores ROVI's business model and revenue generation prowess.

LABFF Intrinsic Value
94.03 USD
Undervaluation 4%
Intrinsic Value
Price $90.61
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett